These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17611692)

  • 21. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
    Wang YM; Hu LX; Liu ZM; You XF; Zhang SH; Qu JR; Li ZR; Li Y; Kong WJ; He HW; Shao RG; Zhang LR; Peng ZG; Boykin DW; Jiang JD
    Clin Cancer Res; 2008 Oct; 14(19):6218-27. PubMed ID: 18829501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE.
    Woyke T; Pettit GR; Winkelmann G; Pettit RK
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3580-4. PubMed ID: 11709343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.
    Verdier-Pinard P; Kepler JA; Pettit GR; Hamel E
    Mol Pharmacol; 2000 Jan; 57(1):180-7. PubMed ID: 10617693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice.
    Zhang ZM; Yang XY; Deng SH; Xu W; Gao HQ
    Chin Med J (Engl); 2007 Aug; 120(15):1336-42. PubMed ID: 17711740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
    Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
    J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model.
    Mohammad RM; Limvarapuss C; Wall NR; Hamdy N; Beck FW; Pettit GR; Al-Katib A
    Int J Oncol; 1999 Aug; 15(2):367-72. PubMed ID: 10402249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
    Beauparlant P; Bédard D; Bernier C; Chan H; Gilbert K; Goulet D; Gratton MO; Lavoie M; Roulston A; Turcotte E; Watson M
    Anticancer Drugs; 2009 Jun; 20(5):346-54. PubMed ID: 19369827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma.
    Mohammad RM; Pettit GR; Almatchy VP; Wall N; Varterasian M; Al-Katib A
    Anticancer Drugs; 1998 Feb; 9(2):149-56. PubMed ID: 9510501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gold (III) porphyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon cancer.
    Tu S; Wai-Yin Sun R; Lin MC; Tao Cui J; Zou B; Gu Q; Kung HF; Che CM; Wong BC
    Cancer; 2009 Oct; 115(19):4459-69. PubMed ID: 19572413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined electric field and ultrasound therapy as a novel anti-tumour treatment.
    Larkin J; Soden D; Collins C; Tangney M; Preston JM; Russell LJ; McHale AP; Dunne C; O'Sullivan GC
    Eur J Cancer; 2005 Jun; 41(9):1339-48. PubMed ID: 15913991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
    Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
    Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10.
    Pettit GR; Hogan F; Toms S
    J Nat Prod; 2011 May; 74(5):962-8. PubMed ID: 21534541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive study of sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines.
    Otrubova K; Lushington G; Vander Velde D; McGuire KL; McAlpine SR
    J Med Chem; 2008 Feb; 51(3):530-44. PubMed ID: 18186604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacologic basis for antibody-auristatin conjugate activity.
    Alley SC; Zhang X; Okeley NM; Anderson M; Law CL; Senter PD; Benjamin DR
    J Pharmacol Exp Ther; 2009 Sep; 330(3):932-8. PubMed ID: 19498104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-activity relationship of kahalalide F synthetic analogues.
    Jiménez JC; López-Macià A; Gracia C; Varón S; Carrascal M; Caba JM; Royo M; Francesch AM; Cuevas C; Giralt E; Albericio F
    J Med Chem; 2008 Aug; 51(16):4920-31. PubMed ID: 18672864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
    Chung F; Liu J; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.
    Maderna A; Doroski M; Subramanyam C; Porte A; Leverett CA; Vetelino BC; Chen Z; Risley H; Parris K; Pandit J; Varghese AH; Shanker S; Song C; Sukuru SC; Farley KA; Wagenaar MM; Shapiro MJ; Musto S; Lam MH; Loganzo F; O'Donnell CJ
    J Med Chem; 2014 Dec; 57(24):10527-43. PubMed ID: 25431858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.